Contrasting Vicarious Surgical (NYSE:RBOT) & IDEXX Laboratories (NASDAQ:IDXX)

Vicarious Surgical (NYSE:RBOT) and IDEXX Laboratories (NASDAQ:IDXX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Vicarious Surgical and IDEXX Laboratories, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1	2	0	0	1.67
IDEXX Laboratories	0	4	7	0	2.64

Vicarious Surgical presently has a consensus price target of $7.00, suggesting a potential upside of 677.78%. IDEXX Laboratories has a consensus price target of $751.00, suggesting a potential upside of 33.27%. Given Vicarious Surgical’s higher probable upside, equities analysts clearly believe Vicarious Surgical is more favorable than IDEXX Laboratories.

Institutional and Insider Ownership

47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 9.5% of Vicarious Surgical shares are owned by company insiders. Comparatively, 0.8% of IDEXX Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Vicarious Surgical has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.

Profitability

This table compares Vicarious Surgical and IDEXX Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
IDEXX Laboratories	24.63%	70.87%	32.56%

Valuation & Earnings

This table compares Vicarious Surgical and IDEXX Laboratories”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22 million	($6.69)	-0.13
IDEXX Laboratories	$4.45 billion	10.00	$1.06 billion	$13.58	41.50

IDEXX Laboratories has higher revenue and earnings than Vicarious Surgical. Vicarious Surgical is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

IDEXX Laboratories beats Vicarious Surgical on 11 of the 13 factors compared between the two stocks.

About Vicarious Surgical

Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

About IDEXX Laboratories

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.